Werewolf Therapeutics (HOWL) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Verrica Pharmaceuticals (VRCA) over the past year, gaining 8.4% versus a loss of 34.9%. Over five years, HOWL leads with a -93.7% price change compared with -97.4% for VRCA. Verrica Pharmaceuticals is the larger company by market cap ($47.1 million vs $46.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | VRCA |
|---|---|---|
| Share price | $0.9466 | $2.74 |
| Market cap | $46.00M | $47.07M |
| 1-day change | -3.97% | -5.03% |
| YTD return | +49.31% | -67.03% |
| 1-year return | +8.43% | -34.92% |
| 5-year return | -93.68% | -97.38% |
| EPS (TTM) | $-0.58 | $-2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $35.58M |
| Revenue growth (YoY) | — | +370.22% |
| Net income (latest FY) | $-60.82M | $-17.89M |
| Operating margin | — | -34.25% |
| Net margin | — | -50.27% |
| 52-week high | $1.20 | $9.82 |
| 52-week low | $0.27 | $2.73 |
| Distance from 52-week high | -21.12% | -72.10% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +639.49% | +404.74% |
| Average volume | 1.08M | 68.78K |
| Shares outstanding | 48.60M | 17.18M |
| Employees | 39 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed VRCA by 43.3 percentage points over the past year.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
HOWL vs VRCA FAQ
Which is bigger, Werewolf Therapeutics or Verrica Pharmaceuticals?
Verrica Pharmaceuticals (VRCA) is larger, with a market capitalization of $47.07M compared with $46.00M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, HOWL or VRCA?
HOWL returned +8.43% over the past 12 months, compared with -34.92% for VRCA (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and Verrica Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.